Bernstein reaffirms Market Perform rating and $30 price target for Pfizer after $6B deal.
From Yahoo Finance: 2025-05-21 14:22:00
Bernstein analysts reaffirmed Market Perform rating and $30 price target for Pfizer Inc. following $6 billion licensing deal with 3SBio Inc. for cancer treatment SSGJ-707. Deal raises questions about Pfizer’s collaboration with Summit Therapeutics.
Pfizer and Summit collaborating on clinical trials combining Pfizer’s ADCs with Summit’s Ivosidenib. Importance of Pfizer’s plans to produce SSGJ-707 in US highlighted amid policy debates on tariffs. Strategic reasons cited for Pfizer licensing SSGJ-707, no expected changes in Pfizer’s partnership with Summit.
Analysts see potential for PFE to grow, but believe AI stocks offer greater promise with lower downside risk. Report suggests exploring AI stocks with 100x upside potential over PFE. No promotional content included in the article.
Read more at Yahoo Finance: Bernstein Reaffirms Pfizer Rating After $6B Cancer Treatment Deal